News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
210,976 Results
Type
Article (9360)
Company Profile (16)
Press Release (201600)
Multimedia
Podcasts (6)
Webinars (6)
Section
Business (80217)
Career Advice (453)
Deals (11836)
Drug Delivery (20)
Drug Development (24595)
Employer Resources (53)
FDA (4598)
Job Trends (4399)
News (120559)
Policy (9078)
Tag
Academia (714)
Adcomms (11)
Allergies (26)
Alliances (14754)
ALS (18)
Alzheimer's disease (433)
Antibody-drug conjugate (ADC) (30)
Approvals (4647)
Artificial intelligence (77)
Autoimmune disease (3)
Automation (3)
Bankruptcy (75)
Best Places to Work (3722)
BIOSECURE Act (3)
Biosimilars (26)
Biotechnology (15)
Bladder cancer (19)
Brain cancer (8)
Breast cancer (57)
Cancer (659)
Cardiovascular disease (40)
Career advice (381)
Career pathing (11)
CAR-T (28)
Cell therapy (101)
Cervical cancer (7)
Clinical research (20542)
Collaboration (242)
Compensation (36)
Complete response letters (4)
COVID-19 (699)
CRISPR (13)
C-suite (95)
Cystic fibrosis (20)
Data (683)
Decentralized trials (1)
Denatured (3)
Depression (10)
Diabetes (85)
Diagnostics (2155)
Digital health (6)
Diversity (1)
Diversity, equity & inclusion (15)
Drug discovery (35)
Drug pricing (18)
Drug shortages (2)
Duchenne muscular dystrophy (13)
Earnings (43835)
Editorial (4)
Employer branding (8)
Employer resources (48)
Events (29955)
Executive appointments (237)
FDA (4934)
Frontotemporal dementia (3)
Funding (151)
Gene editing (26)
Generative AI (8)
Gene therapy (73)
GLP-1 (179)
Government (1095)
Grass and pollen (1)
Guidances (35)
Healthcare (5519)
Huntington's disease (2)
IgA nephropathy (2)
Immunology and inflammation (15)
Indications (12)
Infectious disease (739)
Inflammatory bowel disease (40)
Inflation Reduction Act (1)
Influenza (18)
Intellectual property (28)
Interviews (66)
IPO (5953)
IRA (6)
Job creations (872)
Job search strategy (349)
Kidney cancer (7)
Labor market (2)
Layoffs (85)
Leadership (5)
Legal (1741)
Liver cancer (21)
Lung cancer (125)
Lymphoma (50)
Machine learning (1)
Management (19)
Manufacturing (71)
MASH (6)
Medical device (4522)
Medtech (4522)
Mergers & acquisitions (6001)
Metabolic disorders (150)
Multiple sclerosis (21)
Neurodegenerative disease (19)
Neuropsychiatric disorders (2)
Neuroscience (568)
NextGen: Class of 2025 (1694)
Non-profit (1242)
Now hiring (2)
Obesity (72)
Opinion (44)
Ovarian cancer (25)
Pain (14)
Pancreatic cancer (21)
Parkinson's disease (55)
Partnered (1)
Patents (41)
Patient recruitment (28)
Peanut (18)
People (19967)
Pharmaceutical (9)
Phase I (5554)
Phase II (8745)
Phase III (7808)
Pipeline (487)
Policy (14)
Postmarket research (879)
Preclinical (2262)
Press Release (16)
Prostate cancer (28)
Psychedelics (3)
Radiopharmaceuticals (89)
Rare diseases (73)
Real estate (1600)
Recruiting (20)
Regulatory (6830)
Reports (11)
Research institute (686)
Resumes & cover letters (63)
Rett syndrome (1)
RSV (12)
Schizophrenia (23)
Series A (30)
Series B (21)
Service/supplier (1)
Sickle cell disease (11)
Spinal muscular atrophy (28)
Sponsored (7)
Startups (854)
Stomach cancer (4)
Supply chain (14)
Tariffs (6)
The Weekly (3)
Vaccines (191)
Venture capitalists (8)
Weight loss (32)
Women's health (5)
Worklife (5)
Date
Today (41)
Last 7 days (291)
Last 30 days (788)
Last 365 days (9363)
2025 (2975)
2024 (10309)
2023 (12391)
2022 (17011)
2021 (18191)
2020 (17026)
2019 (14647)
2018 (11295)
2017 (11604)
2016 (10647)
2015 (13018)
2014 (9123)
2013 (7068)
2012 (7752)
2011 (8147)
2010 (7101)
Location
Africa (265)
Alabama (8)
Arizona (37)
Arkansas (1)
Asia (14905)
Australia (2754)
California (1517)
Canada (583)
China (201)
Colorado (68)
Connecticut (61)
Delaware (43)
Europe (36907)
Florida (265)
Georgia (52)
Idaho (25)
Illinois (129)
India (8)
Indiana (96)
Iowa (1)
Japan (86)
Kansas (23)
Kentucky (6)
Louisiana (6)
Maine (39)
Maryland (215)
Massachusetts (1083)
Michigan (72)
Minnesota (104)
Missouri (20)
Montana (12)
Nebraska (6)
Nevada (33)
New Hampshire (24)
New Jersey (596)
New Mexico (5)
New York (408)
North Carolina (290)
North Dakota (2)
Northern California (633)
Ohio (55)
Oklahoma (3)
Oregon (4)
Pennsylvania (368)
Puerto Rico (4)
Rhode Island (7)
South America (447)
South Carolina (9)
Southern California (638)
Tennessee (19)
Texas (195)
United States (5989)
Utah (53)
Virginia (21)
Washington D.C. (11)
Washington State (143)
West Virginia (1)
Wisconsin (17)
210,976 Results for "janssen cilag international nv".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.
May 1, 2024
·
14 min read
MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (“Janssen PMP”) are pleased to announce a significant expansion to their existing Exclusive Evaluation and Option Agreement
September 6, 2023
·
9 min read
MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”), and JANSSEN PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
May 23, 2023
·
7 min read
Press Releases
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
April 24, 2025
·
5 min read
Press Releases
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
April 8, 2025
·
1 min read
Press Releases
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update
April 29, 2025
·
27 min read
Business
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
January 8, 2024
·
2 min read
Press Releases
NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24th
April 7, 2025
·
1 min read
Press Releases
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025
April 17, 2025
·
3 min read
Press Releases
Press Release Biocartis NV: Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay
April 2, 2025
·
4 min read
1 of 21,098
Next
